@article { , title = {Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?}, abstract = {The median survival for patients with malignant pleural mesothelioma remains extremely poor and there is a need for the development of more effective treatment modalities. The epidermal growth factor receptor is frequently over-expressed in malignant pleural mesothelioma samples and therefore may be a potential therapeutic target. Targeted EGFR therapy has been successful in non-small cell lung cancer using small molecule tyrosine kinase inhibitors and in colorectal cancer using monoclonal anti-EGFR antibodies. However, phase II clinical trials based on EGFR tyrosine kinase inhibitor therapy have so far not shown promise in mesothelioma. This review includes a background to targeted EGFR treatment strategies, explores putative therapy resistance mechanisms, including the role of predictive biomarkers, and describes the current status of targeted EGFR therapeutic strategies for mesothelioma patients.}, doi = {10.1016/j.ctrv.2010.11.004}, eissn = {1532-1967}, issn = {0305-7372}, issue = {7}, journal = {Cancer treatment reviews}, note = {Batch 006. Output ID 38540.}, pages = {533-542}, publicationstatus = {Published}, publisher = {Elsevier}, url = {https://hull-repository.worktribe.com/output/409551}, volume = {37}, keyword = {Health and Health Inequalities, Oncology, Radiology Nuclear Medicine and imaging, General Medicine}, year = {2011}, author = {Agarwal, Vijay and Lind, Michael J. and Cawkwell, Lynn} }